Ultherapy Explained — From MFU vs HIFU to Transducer Depths and DeepSEE

Three-Line Summary

• Ultherapy focuses ultrasound the way a magnifying glass focuses sunlight, creating micro-coagulation points (TCPs) at 60–70 °C. That mechanism is fundamentally different from radiofrequency, which heats the dermis broadly.
• The frequency of the transducer sets the depth of the focal point. But the real depth of the SMAS and the dermis differs from person to person and from area to area, so the number printed on a transducer is not enough to target the intended layer. That is why we read the layers on DeepSEE real-time ultrasound imaging before delivering energy.
• Home HIFU devices, the ones marketed as at-home Ultherapy, differ fundamentally in frequency, output and the absence of imaging, so the same kind of SMAS lifting is not a reasonable expectation. ABLE Dermatology uses Ulthera Prime (Merz).

HIFU, MFU and MFU-V Are Not the Same Word

Terminology is the first thing to sort out when explaining Ultherapy. Advertising copy treats HIFU and Ultherapy as interchangeable, but they are in fact three terms nested inside one another. Once that is clear, everything that follows — transducers, depths, home devices — becomes much simpler.

• HIFU (high-intensity focused ultrasound) — the broad category covering any technology that concentrates ultrasound energy at a single point. In medicine it is a wide concept, used not only for aesthetic purposes but in fields such as tumor treatment.
• MFU (micro-focused ultrasound) — within HIFU, the precision approach that creates very small thermal coagulation points of under 1 mm³. The defining point is how small a change it leaves in the tissue.
• MFU-V (MFU with visualization) — MFU combined with real-time ultrasound imaging. Ultherapy belongs here, and the V stands for Visualization, meaning you can see what you are treating.

Ultherapy is an MFU-V device that received FDA clearance in 2009, and it is known as one of the few non-surgical options able to target the SMAS (superficial musculoaponeurotic system) directly. What matters here is not the clearance year or the name, but that the technology for creating precise coagulation points (MFU) and the ability to see where those points are placed (V) sit in the same device.

Radiofrequency Works a Different Way

Both are filed under lifting, but each family delivers energy differently. Radiofrequency (RF) devices such as Density, which we use at ABLE Dermatology, heat the dermis broadly to drive collagen remodeling, while Ultherapy concentrates energy at a point and creates change only at a set depth, point by point. Broad heating versus discrete points — that is the difference.

Because of that, the two families are good at different things. Broad heating has the advantage in surface texture and overall dermal firmness; focusing at a point allows you to target a deep supporting layer selectively. It is less a question of which is better than of which layer the sagging started in.

Why the Distinction Matters in Practice

Calling a device MFU requires at least three things to be established: that coagulation points actually form in human skin, that they are as small as roughly 1 mm³, and that the temperature at that point rises into the range where collagen denatures. Where none of this has been confirmed histologically, calling a device the same technology simply because it focuses ultrasound stretches the category.

The home-device discussion later in this article comes back to the same place. Focusing ultrasound does not by itself make a treatment equivalent. What size of coagulation point forms, and at what depth — that is where the real difference lies.

How Micro-Coagulation Points (TCPs) Form

Ultherapy leaves micro-coagulation points (thermal coagulation points, TCPs) inside the skin. Many patients find it hard to picture change happening underneath with no wound and no crusting on the surface, so let us start there.

It Works Like a Magnifying Glass

Picture focusing sunlight through a magnifying glass. The air the light passes through stays cool, but at the focal point the temperature climbs high enough to burn paper. The focused ultrasound in Ultherapy behaves the same way. In the epidermis and the upper dermis the beam passes through at low energy density, so the tissue is spared; only at the moment it reaches the focus does the energy convert to heat and the temperature rise sharply.

At that point the tissue reaches 60–70 °C in a fraction of a second. That range is not an arbitrary number: it is the threshold at which collagen denatures and begins to contract. Move even slightly away from the focus and the temperature drops off steeply, so surrounding tissue is relatively protected. Enough energy to denature protein is concentrated into a very small space.

Frequency Determines Depth

With ultrasound, the higher the frequency, the shorter the wavelength and the sooner the energy is spent near the surface, and the lower the frequency, the longer the wavelength and the deeper it penetrates. Ultherapy divides roughly the 4–10 MHz range across its transducers, and that difference in frequency is exactly the difference in focal depth. Changing transducers effectively means changing frequency to move the focal distance.

From TIZ to TCP — Why the Term Changed

Early studies used thermal injury zone (TIZ) rather than the TCP we use today. On histology after treatment with the 4.5 mm transducer, the change appeared not as a single point but as a column of heat running upward from the SMAS, and the 3.0 mm transducer likewise produced an inverted-cone area of coagulation extending upward from its target depth.

Those findings are still cited to argue that "the energy does not land exactly where the screen shows it, so there is no reason to image at all." But that work was carried out at high energy settings of 2.3–8.0 J, far above what is used in everyday practice. Later studies at lower energies (1.2 J and below) found no damage to the surrounding tissue and discrete micro-coagulation points rather than a visible column of heat.

In short, under current clinical settings it is more accurate to say that a small coagulation point forms at the depth aimed for, which makes the choice of depth more important, not less. The smaller and more precise the point, the more clearly it is wasted when it lands in the wrong layer.

Why Such Small Points Produce Change

If a single coagulation point is smaller than 1 mm³, it is natural to ask how something that small changes sagging. Studies have found meaningful change in the tissue surrounding each point even though the point itself is minute. One point does not change a face; many points, spaced and oriented in a deliberate pattern, change the tension across the whole layer.

So Ultherapy is closer to a treatment where the depth and pattern of the points decide the result, rather than the power of any single shot. Two conditions have to hold at once for the intended change to appear: enough energy concentrated in a very small space to denature collagen, and that point placed in the layer it was meant for.

Transducer Depths — 1.5 mm, 3.0 mm and 4.5 mm

Each Ultherapy transducer uses a different frequency, so each focuses at a different depth and reaches different tissue. The number in the name is not a product tier — it is the focal distance in millimeters.

1.5 mm — Superficial Dermis

Running at around 10 MHz, it targets the papillary and upper reticular dermis, the layer where microvessels, nerve endings, type III collagen, elastin fibers and fibroblasts sit. It is used mainly for fine superficial lines around the eyes, forehead and mouth, for texture concerns such as skin surface and pores, and on thin-skinned areas like the neck and décolletage.

3.0 mm — Deep Dermis and the Junction

Running at around 7–8 MHz, it targets from the upper reticular dermis down to the junction between dermis and subcutaneous fat. That is the layer of thick type I collagen, elastin, the top of the fat lobules and the fibrous septae. It is used actively for overall firmness of the face and neck and for moderate laxity such as cheek descent and a softening jawline.

4.5 mm — The SMAS

Running at around 4 MHz, it targets the SMAS and the deep subcutaneous fat. The SMAS is the fibromuscular fascia that wraps the facial muscles, the layer that acts as the scaffold holding against descent. It is used when the goal is structural lifting: moderate or greater cheek descent, jawline laxity, neck sagging. Studies report that when the SMAS lies near 4.5 mm and treatment is delivered correctly, the target layer can be stimulated while the epidermis, dermis and fat layer are spared.

The Choice Changes with the Area

Transducer choice also depends on where the change you are treating actually sits. Even within one face, the layer structure and the goal differ from area to area.

• Lower face and under the chin — when a blurred jawline and a descending cheek are the main concern, the deep layer that reaches the SMAS takes the lead.
• Midface (anterior cheek and temple) — the deep dermis and the SMAS are approached separately in order to treat cheek descent and laxity together.
• Neck and décolletage — thinner skin and different underlying structures call for a more conservative choice of depth.
• Fine surface lines and texture around the eyes, forehead and mouth — this belongs to the superficial dermis rather than the deep layers.

In practice we rarely use a single transducer; we combine depths. Two-layer treatment with 3.0 mm and 4.5 mm is the most common, supported by study results reporting greater improvement than 4.5 mm alone. Where texture needs attention as well, 1.5 mm is added for a three-layer plan.

At ABLE Dermatology, Ulthera Prime is run mainly with the 4.5 mm and 3.0 mm transducers, with improvement in sagging as the main goal. Which combination goes where, however, is not decided by the numbers on the transducers alone. The next section explains why.

The Same 4.5 mm Reaches a Different Layer in Different People

Read this far and it looks neatly settled: 1.5 mm for the superficial dermis, 3.0 mm for the deep dermis, 4.5 mm for the SMAS. If it really were that fixed, there would be no reason to look at a screen. Real faces are not that uniform.

Thickness Varies by Zone

Skin thickness differs by zone of the face, and studies have repeatedly confirmed that it also differs with sex and age. Subcutaneous fat thickness varies by zone as well, and the result is that the depth at which the SMAS sits varies from person to person and from area to area. The temple, the anterior cheek, the jawline and the neck are structures that differ in layer composition and thickness to begin with.

So the Number Is a Coordinate, Not a Promise

The 4.5 mm printed on a transducer means the distance at which the beam focuses, not a guarantee that the SMAS lies at that depth. With the same 4.5 mm transducer, a coagulation point can form deeper than intended in someone whose SMAS is shallow, and short of the target in someone whose SMAS is deep.

• Shallow SMAS — the focus can pass the target layer and reach deeper structures.
• SMAS at a suitable depth — the coagulation point forms in the intended layer and contraction happens as planned.
• Thick fat with a deep SMAS — the focus may fall short of the SMAS and stop within the fat layer.

The gap widens most in people with thin skin and people with thick subcutaneous fat. Thin skin makes it easy to overshoot the target layer at a given depth; thick fat makes it easy to fall short. Add the fact that layer thickness changes with age, and the right depth this time can differ from the one used on the same area a few years ago.

These three cases are why the same device, the same transducer and the same energy produce different results. Understanding how Ultherapy works ultimately means matching the depth at which the device creates its coagulation points to the depth at which the target layer actually sits in that person's face. DeepSEE is the feature that makes that match possible.

DeepSEE — What It Means to Treat While Watching

DeepSEE is the real-time ultrasound imaging built into Ultherapy. Place the transducer on the skin and a cross-section of the tissue beneath appears on screen, with the epidermis, dermis, subcutaneous fat and SMAS separated as bands of different brightness. This is exactly what the V in MFU-V refers to.

What You See on the Screen

Ultrasound imaging sounds unfamiliar, but what appears on screen is simple. Tissues reflect ultrasound to different degrees, so the layers show up as bands of different brightness.

• Epidermis and dermis — the uppermost band, relatively bright and dense.
• Subcutaneous fat — the darker, looser zone below it, varying widely in thickness between people.
• SMAS — a distinct band running horizontally beneath the fat layer. How many millimeters down that band sits is what guides transducer choice.

How We Explain It in Clinic

In the consultation room we put it this way. Even with the same rifle, firing through a scope is not the same as roughly lining up the direction and firing. In Ultherapy, DeepSEE is the scope. Before pressing the button we confirm with our own eyes how many millimeters down the SMAS lies at that spot, choose the transducer and the placement that suit that depth, and only then deliver the energy. The order becomes confirm, choose, treat.

What Happens If You Do Not Check

Suppose the three cases above were all treated with the 4.5 mm transducer alone.

• SMAS at a shallow 3.8 mm — the 4.5 mm focus can pass the SMAS and reach deeper structures. Instead of the intended contraction, that becomes unwanted stimulation.
• SMAS at 4.3 mm — the focus lands just past the SMAS and contraction happens as intended.
• Thick fat, SMAS at 5.2 mm — the focus falls short of the SMAS, the expected lift is hard to obtain, and a coagulation point created in the middle of the fat layer can lead to a localized depression.

All three had the same treatment, but only some of them get what was intended. Treating without checking raises both the risk of an underwhelming result and the risk of an unwanted reaction. The difference is clearest with transducers that work deep, such as the 3.0 mm and the 4.5 mm.

Does Watching the Screen Take Longer?

People do point out that checking the screen adds time, and since it is an extra step, the session does run slightly longer. But layer depth does not shift dramatically within one area, so checking each time we move to a new zone does not lengthen treatment substantially. Skipping that check to save time means treating without knowing which of the three cases above you are dealing with.

The Device We Use — Ulthera Prime

ABLE Dermatology uses Ulthera Prime (Merz), the next-generation model from the same manufacturer as the earlier Ultherapy, introduced in Korea in 2025. Having read this far, you will recognize what changed in this model without much explanation, because the improvements are on the imaging side rather than the delivery side.

What Changed

• Imaging range — where the previous model could visualize to about 4.5 mm, Ulthera Prime images to about 8 mm. The treatment depth has not increased; the visible range has widened.
• Screen size and clarity — a larger screen and a sharper image make the boundaries between layers easier to distinguish.
• Treatment speed — faster processing means the same number of shots can be delivered in less time.
• Noise and sensation — noise and perceived stimulation during treatment are reported to be lower than on the previous model.

What Did Not Change

What stayed the same is equally clear. The maximum treatment depth is still 4.5 mm, and the handpieces, the delivery principle and the mechanism behind the result are identical. Prime does not mean the device now treats a new layer or works in a fundamentally different way.

So we describe Ulthera Prime as a device that raises the precision of assessment and the consistency of treatment, not one that changes the kind of result. If, as we have seen, the largest variable in an Ultherapy result is whether the depth of the target layer was read correctly, then seeing deeper and more clearly acts directly on that variable. It helps most on thick skin and in areas where the layer structure is harder to read, and individual results vary.

How Home HIFU Devices (the So-Called At-Home Ultherapy) Differ

As home HIFU devices have become more common, descriptions such as "the same principle as Ultherapy", "4.5 mm tip" and "targets the SMAS" come up often, and patients ask about them regularly in clinic. Measured against the principles set out above, the differences appear at three levels. This is not about any one product; it is about the physical constraints of the device category itself.

1) A Different Category — HIFU and MFU

Most home devices fall under HIFU in the broad sense. As covered above, calling something MFU requires histological evidence that coagulation points on the order of 1 mm³ actually form in human skin and that the temperature rises into the denaturation range, and for home devices that evidence is often not presented. Some demonstrate white dots produced by firing into a clear plastic sheet as proof of coagulation, but plastic and human skin are materials that respond to heat differently, so the two are hard to treat as the same phenomenon.

2) The Frequency Does Not Match the Depth

Ultrasound reaches shallower at higher frequencies and deeper at lower ones. On Ultherapy, the transducer that targets the SMAS at 4.5 mm runs at about 4 MHz, while about 7 MHz belongs to the 3.0 mm transducer. Yet a good number of home products claiming to reach the SMAS at 4.5 mm use the 7 MHz band. Physically, 7 MHz corresponds to a depth near 3 mm, so claiming to target the 4.5 mm layer at that frequency does not fit the behavior of ultrasound.

3) Device Classification and the Structural Limit on Output

Ultherapy genuinely brings the focus to 60–70 °C, and because misuse can cause problems, it is classified as a medical device and used by medical professionals. Home units are classified as beauty devices and designed to be used by oneself at home. That is where a structural constraint appears.

• If a home device really did reach 60–70 °C, an effect might be expected, but at that moment it is already more heat than is comfortable to handle by oneself at home.
• If the output is low enough to use casually at home, it most likely never reaches the temperature range where collagen denatures, so no coagulation point forms.

That makes "the same level of result at home, and with no burden" a claim that has trouble satisfying both conditions at once. On top of that, home devices have no imaging to confirm the layers, so there is no way at all to deal with the person-to-person depth variation described above.

Will Frequent, Long-Term Use Not Add Up?

This is the question we hear most. There are two reasons it is hard to make up for by accumulation. First, if the temperature threshold where change begins is never reached, adding sessions does not stack up the same kind of change. Second, if the depth reached is different, the layer being targeted is different too. No amount of repetition with a device acting near 3 mm makes it the same as treating the SMAS at 4.5 mm.

None of this means you should not use a home device. What a home device can reasonably offer is closer to a short-lived tightening sensation from surface warming, and it is a tool with a different purpose from the directional SMAS lifting Ultherapy aims at. Keeping the two apart narrows the gap between expectation and result, whichever you choose.

Direction (Vectors) and the Order in Which Results Appear

Finally, how the coagulation points that form translate into improvement in sagging. This is also the point that separates Ultherapy from other energy devices.

Lifting and Tightening Are Not the Same Word

The single word lifting usually covers both, but the two concepts are distinct. Tightening is the change of loose skin sitting more snugly against the face, while lifting is the change of a descended structure being moved upward, with direction. Modalities that heat broadly, such as radiofrequency and microwave, are by mechanism closer to tightening.

Vector Lifting — The Direction in Which Points Are Arranged

With Ultherapy, the direction in which the coagulation points are arranged changes the direction in which contraction occurs. This is called vector (directional) lifting. The 4.5 mm transducer targeting the SMAS is delivered along the direction the muscles run, with reversing descent as the goal, while the 3.0 mm transducer follows the same approach where the SMAS is shallow and is delivered in a grid or somewhat more vertically when treating the dermis or subcutaneous fat, focusing on tightening.

In other words, even with the same number of shots, the plan includes reading the direction and degree of descent first, then designing the treatment to run against it. That is why Ultherapy is described as one of the few non-invasive options able to give direction.

Results Come in Two Stages

Change from Ultherapy appears twice, with a gap between. Patients who do not know this sequence are easily disappointed partway through, so we always go over it before treatment.

• Immediate change (right after treatment to 2 weeks) — as the coagulation points form, existing collagen contracts immediately and you feel a tightening. It tends to be most noticeable with the 4.5 mm on the SMAS, and the directional change from vector lifting is felt to some degree as well.
• Temporary decline (2–4 weeks) — the contracted collagen is still weak and new collagen has not yet formed, so what you feel can fade. This is not a sign that something went wrong; it is the middle stretch of the regenerative response.
• Delayed change (2–12 weeks) — new collagen and elastic fibers form and change builds gradually. It tends to be most evident around three months, with individual variation in both timing and degree.

So Ultherapy is closer to a treatment judged by the change at three months rather than by the impression right afterward. Treating the immediate tightening as the final result makes the 2–4 week mark discouraging; conversely, rushing to add another treatment before that stretch has passed makes it hard to tell which treatment produced which change. How long the result holds also depends on skin thickness, how quickly laxity progresses and lifestyle, so it is more accurate to set the timing of the next session while following the course together.

From Examination to Treatment

A board-certified dermatologist examines you directly, identifies the layer the problem sits in, decides the device and the parameters, and the same dermatologist then carries out the treatment. Treatment is not recommended to you by a consultant.

The number of sessions, the intervals, the timing of maintenance and the cost are agreed together before the first treatment.